Largest controlled safety study of a recombinant meningococcal serogroup B vaccine.
SAEs occurred in lower percentage of bivalent rLP2086 group than control group.
SAEs related to vaccine were rare.
Rates of medically-attended AEs were similar between vaccine groups.
Bivalent rLP2086 was safe and tolerable in adolescents and young adults 10–25 years.